Challenges in the treatment of depression with psychotic features

Biological Psychiatry

Volumn 53, Issue 8, 2003, Pages 680-690

  Rothschild, Anthony J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Delusional depression; Major depression with psychotic features; Psychotic depression

Indexed keywords

AMINOGLUTETHIMIDE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DESIPRAMINE; ENZYME; FLUOXETINE; GLUCOCORTICOID ANTAGONIST; HALOPERIDOL; HYDROCORTISONE; IMIPRAMINE; KETOCONAZOLE; LITHIUM; METYRAPONE; MIFEPRISTONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOTEPINE; GLUCOCORTICOID;

AKATHISIA; ANTICHOLINERGIC EFFECT; BIPOLAR DISORDER; BRAIN RADIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG MECHANISM; DYSPHORIA; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; HEALTH SERVICE; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMAGING; MAJOR DEPRESSION; MORBIDITY; MORTALITY; OCCUPATIONAL HEALTH; ONSET AGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOSIS; QUALITY CONTROL; RECURRENT DISEASE; RELAPSE; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SIDE EFFECT; SLEEP PATTERN; SOCIAL ASPECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT PLANNING; BLOOD; DRUG ANTAGONISM; FAMILY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FAMILY; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; LITHIUM; PSYCHOTIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 0038824212     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01747-X     Document Type: Review

References (132)

1. Aberg-Wistedt A, Wistedt B, Bertilsson L (1985): Higher CSF levels of HVA and 5-HIAA in delusional compared to non delusional depression. Arch Gen Psychiatry 42:925-926.
2. Adli M, Rossius W, Bauer M (1999): [Olanzapine in the treatment of depressive disorders with psychotic symptoms]. Nervenarzt 70:68-71.
3. Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Franon M (1983): Bipolar outcome in the course of depressive illness: Phenomenological, familial, and pharmacologic predictors. J Affect Disord 5:115-128.
4. American Psychiatric Association (2000): Practice guideline for the treatment of major depressive disorder (revision). Am J Psychiatry Suppl 157:(suppl 4).
5. American Psychiatric Association Committee on Nomenclature and Statistics (1994): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association.
6. Amsterdam J, Mosley PD, Rosenzweig M (1994): Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketoconazole. In: Nolan W, Zohar J, Roose S, Amsterdam J, editors. Refractory Depression. Chichester, UK: John Wiley & Sons, 199-210.
7. Anand A, Malison R, McDougle CJ, Price LH (1995): Antiglucocorticoid treatment of refractorydepression with ketoconazole: A case report. Biol Psychiatry 37:338-340.
8. Angst J (1961): A clinical analysis of the effects of Tofranil in depression. Psychopharmacologia 2:381-407.
9. Anton RF Jr (1987): Urinary free cortisol in psychotic depression. Biol Psychiatry 22:24-34.
10. Anton RF Jr, Burch EA Jr (1990): Amoxapine versus amitriptyline combined with (208) perphenazine in the treatment of psychotic depression. Am J Psychiatry 147:1203-1208.
11. Anton RF, Sexauer JD (1983): Efficacy of amoxapine in psychotic depression. Am J Psychiatry 140:1344-1347.
12. Aronson TA, Shukla S, Gujavarty K, Hoff A, DiBuono M, Khan E (1988a): Relapse in delusional depression: A retrospective study of the course of treatment. Comp Psychiatry 29:12-21.
13. Aronson TA, Shukla S, Hoff A (1987): Continuation therapy after ECT for delusional depression: A naturalistic study of prophylactic treatments and relapse. Convuls Ther 3:251-259.
14. Aronson TA, Shukla S, Hoff A, Cook B (1988b): Proposed delusional depression subtypes: Preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord 14:69-74.
15. Avery D, Lubrano A (1979): Depression treated with imipramine and ECT: The DeCarolis study reconsidered. Am J Psychiatry 136:559-562.
16. Baldwin RC, Jolley DJ (1986): The prognosis of depression in old age. Br J Psychiatry 574-583.
17. Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, et al (1994): Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up. J Clin Psychiatry 55:295-300.
18. Basso MR, Bornstein RA (1999): Neuropsychological deficits in psychotic versus nonpsychotic unipolar depression. Neuropsychology 13:69-75.
19. Bauer M, Dopfmer S (1999): Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled trials. J Clin Psychopharmacol 19:427-434.
20. Belanoff J, Flores B, Kalezhan M, Sund B, Schatzberg A (2001a): Rapid reversal of psychotic major depression using mifepristone. J Clin Psychopharmacol 21:516-521.
21. Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF (2001b): Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 158:1612-1616.
22. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, et al (2002): An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52:386-392.
23. Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF (1986): Delusional depression, family history, and DST response: A pilot study. Biol Psychiatry 21:1239-1246.
24. Brown RP, Stoll PM, Stokes PE, Frances A, Sweeney J, Kocsis JH, Mann JJ (1988): Adrenocortical hyperactivity in depression: Effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res 23:167-168.
25. Chacko RC, Hurley RA, Jankovic J (1993): Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 5:206-208.
26. Chan CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D (1987): Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 48:197-200.
27. Charney DS, Nelson J (1981): Delusional and nondelusional unipolar depression: Further evidence for distinct subtypes. Am J Psychiatry 138:328-333.
28. Coryell W, Endicott J, Keller M (1987): The importance of psychotic features to major depression: Course and outcome during a 2-year follow-up. Acta Psychiatr Scand 75:78-85.
29. Coryell W, Keller M, Lavori P, Endicott J (1990): Affective syndromes, psychotic features and prognosis I: Depression. Arch Gen Psychiatry 47:651-657.
30. Coryell W, Leon A, Winokur G, Endicott J, Keller MB, Akiskal H, Solomon D (1996): The importance of psychotic features to long term course in depressive disorders. Am J Psychiatry 153:483-489.
31. Coryell W, Pfohl B, Zimmerman M (1984): The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis 172:521-528.
32. Coryell W, Tsuang MT (1982): Primary unipolar depression and the prognostic importance of delusions. Arch Gen Psychiatry 39:1181-1184.
33. Coryell W, Tsuang MT, McDaniel J (1982): Psychotic features in major depression: Is mood congruence important? J Affect Disord 4:227-236.
34. Coryell W, Zimmerman M (1986): Demographic, historical, and symptomatic features of the nonmanic psychoses. J Nerv Ment Dis 174:585-592.
35. Coryell W, Zimmerman M, Pfohl B (1986): Outcome at discharge and six months in major depression. The significance of psychotic features. J Nerv Ment Dis 174:92-96.
36. Dassa D, Kaladjian A, Azorin JM, Giudicelli S (1993): Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 163:822-824.
37. DeBattista C, Solvason HB, Belanoff J, Schatzberg AF (1997): Treatment of psychotic depression. Am J Psychiatry 154:1625-1626.
38. Devanand DP, Bowers MB, Huffman FJ Jr, Nelson JC (1985): Elevated homovanillic acid in depressed females with melancholia and psychosis. Psychiatry Res 15:1-4.
39. Evans DE, Burnett G, Nemeroff CB (1983): The dexamethasone suppression test in the clinical setting. Am J Psychiatry 140:586-589.
40. Flint AJ, Rifat SL (1998): The treatment of psychotic depression in later life: A comparison of pharmacotherapy and ECT. J Geriatr Psychiatry 13:23-28.
41. Frances A, Brown RP, Kocsis JH, Mann JJ (1981): Psychotic depression: A separate entity? Am J Psychiatry 138:831-833.
42. Frangos E, Athanassenas G, Tsitourides S, Psilolignos P, Katsanou N (1983): Psychotic depressive disorder: A separate entity? J Affect Dis 5:259-265.
43. Friedman C, Bowbray MS, Hamilton VJ (1961): Imipramine (Tofranil) in depressive states. J Ment Sci 107:948-953.
44. Gaillard RC, Riondel A, Muller AF, Herrmann W, Baulieu EE (1984): RU 486: A steriod with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Med Sci 81:3879-3882.
45. Gatti F, Eclini L, Gasperini M, Perez J, Zanardi R, Smeraldi E (1996): Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 153:414-416.
46. Ghadirian AM, Englesmann F, Dhar V, Filipini D, Keller R, Chouinard G, Murphy BEP (1995): The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 37:369-375.
47. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL (1977): Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 34:197-204.
48. Glassman AH, Roose SP (1981): Delusional depression: A distinct clinical entity? Arch Gen Psychiatry 38:424-427.
49. Helms PM, Smith RE (1983): Recurrent psychotic depression: Evidence of diagnostic stability. J Affect Disord 5:51-54.
50. Hermann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE (1982): Effet d'un steroide anti-progesterone chez la femme Interuption du cycle menstrul et de la grossese au debut [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. C R Seances Acad Sci III 294:933-938.
51. Hillert A, Maier W, Wetzel H, Benkert O (1992): Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome-a functional approach. Pharmacopsychiatry 25:213-217.
52. Hordern A, Holt NF, Burt CG, Gordon WF (1963): Amitriptyline in depressive states: Phenomenology and prognostic considerations. Br J Psychiatry 109:815-825.
53. Jacobson FM (1995): Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 56:423-429.
54. Jeste DV, Heaton SC, Paulsen JS, Ercoli L, Harris J, Heaton RK (1996): Clinical and neuropsychological comparison of psychotic depression with nonpsychotic depression and schizophrenia. Am J Psychiatry 153:490-496.
55. Johnson J, Horwath E, Weissman MM (1991): The validity of major depression with psychotic features based on a community sample. Arch Gen Psychiatry 48:1075-1081.
56. Kantor SJ, Glassman AH (1977): Delusional depressions: Natural history and response to treatment. Br J Psychiatry 131:351-360.
57. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, et al (1995): Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 56:466-470.
58. Kim DK, Kim BE, Sohn SE, Lim SW, Na DG, Paik CH, et al (1999): Candidate neuroanatomic substrates of psychosis in old-aged depression. Prog Neuropsychopharmacol Biol Psychiatry 23:793-807.
59. Kroessler D (1985): Relative efficacy rates for therapies of delusional depression. Commis Ther 1:173-182.
60. Lamberts SW, Koper JW, Jong FH (1991): The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 73:187-191.
61. Leckman JF, Weisman MM, Prusoff BA, Caruso KA, Merikangas KR, Pauls DL, Kidd KK (1984): Subtypes of depression: Family study perspective. Arch Gen Psychiatry 41:833-838.
62. Eykouras E, Christodoulou GN, Malliaras D, Stefanis C (1994): The prognostic importance of delusions in depression: A 6-year prospective follow-up study. J Affect Disord 32:233-238.
63. Lykouras E, Malliaras D, Christodoulou GN, Papakostas Y, Voulgari A, Tzonou A, Stefanis C (1986): Delusional depression: Phenomenology and response to treatment, a prospective study. Acta Psychiatric Scand 73:324-329.
64. Maj M, Starace F, Pirozzi R (1991): A family study of DSM-III-R schizoaffective disorder, depressive subtype, compared with schizophrenia and psychotic and nonpsychotic major depression. Am J Psychiatry 148:612-616.
65. Malhi GS, Checkley SA (1999): Olanzapine in the treatment of psychotic depression. Br J Psychiatry 174:460.
66. Matuzas W, Meltzer HY, Uhlenhuth EH, Glass RM, Tong C (1982): Plasma dopamine-B-hydroxylase in depressed patients. Biol Psychiatry 17:1415-1424.
67. Mazure CM, Bowers MB, Hoffman F Jr, Miller KB, Nelson JC (1987): Plasma catecholamine metabolites in subtypes of major depression. Biol Psychiatry 22:1469-1472.
68. Meltzer HY, Cho HW, Carroll BJ, Russo P (1976): Serum dopamine-B-hydroxylase activity in the affective psychoses and schizophrenia. Arch Gen Psychiatry 33:585-591.
69. Meyers BS, Greenberg R (1986): Late-life delusional depression. J Affect Disord 11:133-137.
70. Mod L, Rihmer Z, Magyar I, Arato M, Alfoldi A, Bagdy G (1986): Serum DBH activity in psychotic vs. nonpsychotic unipolar and bipolar depression. Psychiatry Res 19:331-333.
71. Muller-Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O (1998): Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 18:111-120.
72. Mulsant BH, Haskett RF, Prudic J, Thase ME, Malone KM, Mann JJ, et al (1997): Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry 154:559-561.
73. Mulsant BH, Sweet BA, Rosen J, Pollack BG, Zubenko GS, Flynn T, et al (2001): A randomized double-blind comparison of nortriptyline plus perphenazine vs. nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry 62:597-604.
74. Murphy BEP, Filipini D, Ghadirian AM (1993): Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU 486. J Psychiatr Neurosci 18:209-213.
75. Murphy BEP, Wolkowitz OM (1993): The pathophysiologic significance of hyperadrenocorticism: Antiglucocorticoid strategies. Psychiatr Ann 23:682-690.
76. Murphy E (1983): The prognosis of depression in old age. Br J Psychiatry 142:111-119.
77. Naber D, Holzbach R, Perro C, Hippius H (1992): Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 160:54-59.
78. Nelson EB, Rielage E, Welge JA, Keck PE Jr (2001): An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry 13:147-151.
79. Nelson EB, Sax KW, Strakowski SM (1998): Attentional performance in patients with with psychotic and nonpsychotic major depression and schizophrenia. Am J Psychiatry 155:137-139.
80. Nelson JC, Bowers MB (1978): Delusional versus unipolar depression: Description and drug response. Arch Gen Psychiatry 35:1321-1328.
81. Nelson JC, Davis JM (1997): DST studies in psychotic depression: A meta-analysis. Am J Psychiatry 154:1497-1503.
82. Nelson JC, Mazure CM (1986): Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 143:363-366.
83. Nelson WH, Khan A, Orr WW (1984): Delusional depression: Phenomenology, neuroendocrine function, and tricyclic antidepressant response. J Affect Disord 6:297-306.
84. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, et al (1985): Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536-540.
85. Olfson M, Marcus S, Sackeim HA, Thompson J, Pincus HA (1998): Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 155:2-29.
86. Pande A, Grunhaus L, Hasket R, Haskett R, Greden JF (1990): Electroconvulsive therapy in delusional and nondelusional depressive disorder. J Affect Disord 19:215-219.
87. Parker G, Hadzi-Pavlovic D, Hickie I, Boyce P, Mitchell P, Wilhelm K, Brodarty H (1991): Distinguishing psychotic and non-psychotic melancholia. J Affect Disord 22:135-148.
88. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F (1992): Psychotic (delusional) depression: A meta-analysis of physical treatments. J Affect Disord 24:17-24.
89. Parsa MA, Ramirez LF, Loula CE, Meltzer HY (1991): Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol 11:330-331.
90. Price LH, Conwell Y, Nelson JC (1983): Eithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 140:318-322.
91. Price LH, Nelson JC, Charney DS, Quinlan DM (1984): Family history in delusional depression. J Affect Disord 6:109-114.
92. Proulx-Ferland E, Cote E, Philibert D, Deraedt R (1982): Potent antiglucocorticoid activity of RU486 on ACTH secretion in vitro and in vivo in the rat. J Steroid Biochem 17:27.
93. Ranjan R, Meltzer HY (1995): Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 40:253-258.
94. Ravaris CL, Sateia MJ, Beroza KW, Noordsy DE, Brinck-Johnsen T (1988): Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry 45:966-967.
95. Rihmer Z, Arato M, Szadoczky E, Revai K, Demeter E, Gyorgy S, Udvarhelyi P (1984): The dexamethasone suppression test in psychotic versus nonpsychotic depression. Br J Psychiatry 145:508-511.
96. Robinson DG, Spiker DG (1985): Delusional depression: A one year follow-up. J Affect Disord 9:79-83.
97. Roose SP, Glassman AH, Walsh BT, Woodring S, Vital-Herne J (1983): Depression, delusions, and suicide. Am J Psychiatry 140:1159-1162.
98. Rothschild AJ (1985): Delusional depression: A review of the literature and current perspectives. McLean Hosp J 10:68-83.
99. Rothschild AJ (1996): Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 19:237-252.
100. Rothschild AJ, Bates KS, Boehringer KL, Syed A (1999): Olanzapine response in psychotic depression. J Clin Psychiatry 60:116-118.
101. Rothschild AJ, Benes F, Hebben N, Woods B, Luciana M, Bakanas E, et al (1989): Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry 26:565-575.
102. Rothschild AJ, Duval SE (in press): How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry.
103. Rothschild AJ, Phillips KA (1999): Selective serotonin reuptake inhibitors and delusional depression. Am J Psychiatry 156:977-978.
104. Rothschild AJ, Samson JA, Besserte MP, Carter-Campell JT (1993a): Efficacy of combination fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54:338-342.
105. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF (1993b): Hypothalamic-pituitary-adrenal axis activity and one-year outcome in depression. Biol Psychiatry 34:392-400.
106. Rothschild AJ, Schatzberg AF (1993): Psychotic depression: A newly recognized subtype. Clin Neurosci 1:75-80.
107. Rothschild AJ, Schatzberg AF (1994): Diagnosis and treatment of psychotic (delusional) depression. In: Grunhaus L, Greden JF, editors. Severe Depressive Disorders. Washington, DC: American Psychiatric Press, 195-207.
108. Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO (1987): Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. Psychiatry Res 20:143-153.
109. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al (2001): Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. A randomized controlled trial. JAMA 285:1299-1307.
110. Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S (1990): The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10:96-104.
111. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY (1991): Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology 41:156 [letter].
112. Schatzberg AF, Posener JA, DeBattista C, Kalehzan M, Rothschild AJ, Shear PK (2000): Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 157:1095-1100.
113. Schatzberg AF, Rothschild AJ (1988): The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Ann N Y Acad Sci 537:462-471.
114. Schatzberg AF, Rothschild AJ (1992): Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 149:733-745.
115. Schatzberg AF, Rothschild AJ (1996): Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV. In: Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW, editors. DSM-IV Source Book, Vol. 2. Washington, DC: American Psychiatric Press, 127-180.
116. Simpson S, Baldwin RC, Jackson A, Burns A (1999): The differentiation of DSM-IIIR psychotic depression in later life from nonpsychotic depression: Comparisons of brain changes measured by multispectral analysis of magnetic resonance brain images, neuropsychological findings, and clinical features. Biol Psychiatry 45:193-204.
117. Spiker DG, Stein J, Rich CL (1985a): Delusional depression and electroconvulsive therapy: One year later. Commis Ther 1:167-172.
118. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al (1985b): The pharmacological treatment of delusional depression. Am J Psychiatry 142:430-436.
119. Strober M, Carlson G (1982): Bipolar illness in aldolescents with major depression: Clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 39:549-555.
120. Strotskopf C, Horn SD (1992): Predicting length of stay for patients with psychosis. Health Serv Res 26:743-766.
121. Thakore JH, Dinan TG (1995): Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 37:364-368.
122. Thase ME, Kupfer DJ, Ulrich RF (1986a): Current status of sleep EEG in the assessment and treatment of depression. In: Burrows GO, Werry JS, editors. Advances in Human Psychopharmacology, Vol. 4. Greenwich, CT: JTI Press.
123. Thase ME, Kupfer DJ, Ulrich RF (1986b): Electroencephalographic sleep in psychotic depression: A valid subtype? Arch Gen Psychiatry 43:886-893.
124. Van der Lely A-J, Foeken K, van der Mast RC, Lamberts SWJ (1991): Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 114:143-144.
125. Weissman MM, Prusoff BA, Merikangas KR (1984): Is delusional depression related to bipolar disorder? Am J Psychiatry 141:892-893.
126. Wilson KG, Kraitberg NJ, Brown JH, Bergamn JN (1991): Electroconvulsive therapy in the treatment of depression: The impact on length of stay. Comp Psychiatry 32:345-354.
127. Wolfersdorf M, Barg R, Konig F, Leibfarth M, Grunewald I (1995): Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: Observation of clinical use. Pharmacopsychiatry 28:56-60.
128. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H (1993): Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 150:810-812.
129. Wood MJ, Rubinstein M (1990): An atypical responder to clozapine. Am J Psychiatry 147:369 [letter].
130. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996): Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153:1631-1633.
131. Zanardi R, Franchini E, Serretti A, Perez J, Smeraldi E (2000): Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study. J Clin Psychiatry 61:26-29.
132. Zarate CA Jr, Rothschild AJ, Fletcher KE, Madrid A, Zapatel J (2000): Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 61:185-189.